New Vabomere antibacterial drugs are approved by the FDA to cause a stir

1. 1 in 5 adults are hospitalized with antibiotic side effects
2. Dirty stethoscope can spread many types of antibiotic-resistant viruses

The Food and Drug Administration of the United States (FDA) has just officially recognized a new antibacterial drug called Vabomere used to treat urinary tract infections in adults.

FDA approves Vabomere drugs as an adult drug with complicated urinary tract infections (cUTI) along with a type of kidney infection known as specific bacterial nephritis.

Vabomere contains meropenem and vaborbaktam, which inhibits certain types of resistance mechanisms to eliminate the mechanism of action of these pathogenic bacteria.

Dr. Edward Cox, Director of the Office of Antimicrobial Products at FDA's Drug Evaluation and Evaluation Center, said: "The FDA is committed to creating new and safe antibacterial drugs available for This FDA approval will provide an additional treatment for patients with cUTI, a serious infection ".

Vabomere has been tested through a clinical trial of 545 adults with cUTI and patients with nephritis. Patients are treated with Vabomere via intravenous route.

Tests showed that 77 percent of patients treated with Vabomere compared with 73 percent of patients treated with piperacillin / tazobactam overcame the symptoms of the disease and urine samples negative for pathogenic bacteria. this.